KYMR - kymeratx.com Price to Earnings Adjusted for Growth Rate

Symbol and logo of brand Kymera Therapeutics (KYMR)

The PEG ratio dynamics on the GURU.Markets chart highlight the protection of Kymera Therapeutics (KYMR) business by patents and strict FDA oversight, with the metric currently standing at 0.00. Growth is driven by investments in the Pegasus R&D platform for combating tumors. The strategy of Kymera Therapeutics (KYMR) is based on the complete elimination of pathogenic proteins, which radically transforms therapeutic approaches to autoimmune pathologies and oncology.

KYMR: kymeratx.com Price/Earnings to Growth Multiple 07/04/2022 - 11/16/2026

Metric breakdowns and analytics for Kymera (KYMR)

- market value and analyst target forecast:
General company analysis:Kymera Therapeutics
Signature product of kymeratx.com

Outsourcing clinical trials and manufacturing allows Kymera Therapeutics (KYMR) to optimize costs, which directly impacts net income dynamics. The ratio of the P/E coefficient to earnings growth rates in the PEG fair value filter determines the extent to which the market price of the stock is justified by the speed of business expansion. Values below one signal that the asset is undervalued, turning this indicator into a tool for identifying high-yield "rockets."